Please use this identifier to cite or link to this item: http://ricaxcan.uaz.edu.mx/jspui/handle/20.500.11845/2556
Full metadata record
DC FieldValueLanguage
dc.contributor208395es_ES
dc.contributor.other0000-0002-6599-7994es_ES
dc.coverage.spatialGlobales_ES
dc.creatorCervantes Villagrana, Rodolfo Daniel-
dc.creatorAlbores García, Damaris-
dc.creatorCervantes Villagrana, Alberto Rafael-
dc.creatorGarcía Acevez, Sara Judit-
dc.date.accessioned2021-06-04T16:45:51Z-
dc.date.available2021-06-04T16:45:51Z-
dc.date.issued2020-06-18-
dc.identifierinfo:eu-repo/semantics/publishedVersiones_ES
dc.identifier.issn2059-3635es_ES
dc.identifier.urihttp://ricaxcan.uaz.edu.mx/jspui/handle/20.500.11845/2556-
dc.description.abstractNormal cells are hijacked by cancer cells forming together heterogeneous tumor masses immersed in aberrant communication circuits that facilitate tumor growth and dissemination. Besides the well characterized angiogenic effect of some tumor-derived factors; others, such as BDNF, recruit peripheral nerves and leukocytes. The neurogenic switch, activated by tumor-derived neurotrophins and extracellular vesicles, attracts adjacent peripheral fibers (autonomic/sensorial) and neural progenitor cells. Strikingly, tumor-associated nerve fibers can guide cancer cell dissemination. Moreover, IL-1β, CCL2, PGE2, among other chemotactic factors, attract natural immunosuppressive cells, including T regulatory (Tregs), myeloid-derived suppressor cells (MDSCs), and M2 macrophages, to the tumor microenvironment. These leukocytes further exacerbate the aberrant communication circuit releasing factors with neurogenic effect. Furthermore, cancer cells directly evade immune surveillance and the antitumoral actions of natural killer cells by activating immunosuppressive mechanisms elicited by heterophilic complexes, joining cancer and immune cells, formed by PD-L1/PD1 and CD80/CTLA-4 plasma membrane proteins. Altogether, nervous and immune cells, together with fibroblasts, endothelial, and bone-marrow-derived cells, promote tumor growth and enhance the metastatic properties of cancer cells. Inspired by the demonstrated, but restricted, power of anti-angiogenic and immune cell-based therapies, preclinical studies are focusing on strategies aimed to inhibit tumor-induced neurogenesis. Here we discuss the potential of anti-neurogenesis and, considering the interplay between nervous and immune systems, we also focus on anti-immunosuppression-based therapies. Small molecules, antibodies and immune cells are being considered as therapeutic agents, aimed to prevent cancer cell communication with neurons and leukocytes, targeting chemotactic and neurotransmitter signaling pathways linked to perineural invasion and metastasis.es_ES
dc.language.isoenges_ES
dc.publisherNaturees_ES
dc.relationhttps://www.nature.com/articles/s41392-020-0205-zes_ES
dc.relation.urigeneralPublices_ES
dc.rightsAtribución-NoComercial-CompartirIgual 3.0 Estados Unidos de América*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/us/*
dc.sourceSignal Transduction and Targeted Therapy Vol. 5, pp. 1-23es_ES
dc.subject.classificationMEDICINA Y CIENCIAS DE LA SALUD [3]es_ES
dc.subject.otherCancer microenvironmentes_ES
dc.subject.otherDrug developmentes_ES
dc.subject.otherTumour immunologyes_ES
dc.titleTumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapieses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
Appears in Collections:*Documentos Académicos*-- M. en Ciencias y Tecnología Química

Files in This Item:
File Description SizeFormat 
Tumor-induced neurogenesis and immune evasion as targets.pdf4,21 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons